Adverse effects of tofacitinib include increased levels of alanine transaminase (ALT) and aspartate aminotransferase (AST), nasopharyngitis, dyspnea [6], anemia, hyperlipidemia, and increased risk of cardiovascular diseases such as leukopenia [7] and thromboembolism. The gene discussed is GPT; the disease is Decreased total leukocyte count.